WO2007055743A3 - Treatment of obesity and related disorders - Google Patents

Treatment of obesity and related disorders Download PDF

Info

Publication number
WO2007055743A3
WO2007055743A3 PCT/US2006/022584 US2006022584W WO2007055743A3 WO 2007055743 A3 WO2007055743 A3 WO 2007055743A3 US 2006022584 W US2006022584 W US 2006022584W WO 2007055743 A3 WO2007055743 A3 WO 2007055743A3
Authority
WO
WIPO (PCT)
Prior art keywords
obesity
related disorders
treatment
agents directed
methods
Prior art date
Application number
PCT/US2006/022584
Other languages
French (fr)
Other versions
WO2007055743A2 (en
Inventor
Jonathan Roth
Alain Baron
David Parkes
Andrew Young
Christen M Anderson
Original Assignee
Amylin Pharmaceuticals Inc
Jonathan Roth
Alain Baron
David Parkes
Andrew Young
Christen M Anderson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2005/039686 external-priority patent/WO2006052608A2/en
Priority claimed from PCT/US2006/011768 external-priority patent/WO2006105345A2/en
Priority claimed from PCT/US2006/017529 external-priority patent/WO2007055728A1/en
Application filed by Amylin Pharmaceuticals Inc, Jonathan Roth, Alain Baron, David Parkes, Andrew Young, Christen M Anderson filed Critical Amylin Pharmaceuticals Inc
Publication of WO2007055743A2 publication Critical patent/WO2007055743A2/en
Publication of WO2007055743A3 publication Critical patent/WO2007055743A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods for treating obesity or obesity related disorders are disclosed. These methods include bariatric surgery in conjunction with the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain.
PCT/US2006/022584 2005-11-01 2006-06-09 Treatment of obesity and related disorders WO2007055743A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/US2005/039686 WO2006052608A2 (en) 2004-11-01 2005-11-01 Treatment of obesity and related disorders
USPCT/US2005/039686 2005-11-01
USPCT/US2006/011768 2006-03-31
PCT/US2006/011768 WO2006105345A2 (en) 2005-03-31 2006-03-31 Compositions and methods for the control, prevention, and treatment of obesity and eating disorders
PCT/US2006/017529 WO2007055728A1 (en) 2005-11-01 2006-05-03 Treatment of obesity and related disorders
USPCT/US2006/017529 2006-05-03

Publications (2)

Publication Number Publication Date
WO2007055743A2 WO2007055743A2 (en) 2007-05-18
WO2007055743A3 true WO2007055743A3 (en) 2007-08-02

Family

ID=38038570

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/022584 WO2007055743A2 (en) 2005-11-01 2006-06-09 Treatment of obesity and related disorders

Country Status (1)

Country Link
WO (1) WO2007055743A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12103951B2 (en) 2022-06-14 2024-10-01 Christopher Joseph Soares Use of CGRP receptor antagonists in neuroprotection and neurological disorders

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009033744A1 (en) * 2007-09-11 2009-03-19 Mondo Biotech Laboratories Ag Use of urodilatin as a therapeutic agent
AU2008303941A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of the peptide Pro-Gly-Thr-Cys-Glu-Ile-Cys-Ala-Tyr-Ala-Ala-Cys-Thr-Gly-Cys as a therapeutic agent
WO2009064298A1 (en) * 2007-11-14 2009-05-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
CA2861392C (en) 2012-01-26 2021-08-17 Christopher J. Soares Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use
WO2013152109A1 (en) * 2012-04-04 2013-10-10 Dana-Farber Cancer Institute, Inc. Trpv4 antagonist and methods of use thereof
JP6538682B2 (en) 2013-07-30 2019-07-03 ソアレス クリストファー ジェイ． CGRP agonist peptide
US10278948B1 (en) * 2015-09-03 2019-05-07 Tian Xia Method for transnasal delivery of anticonvulsant and therapeutic treatments
IL265099B2 (en) 2016-09-02 2024-09-01 Christopher J Soares Pharmaceutical compositions comprising an effective amount of calcitonin gene-related peptide (cgrp) receptor antagonist or pharmaceutically acceptable salt thereof, for treating glaucoma

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030231A1 (en) * 1997-01-07 1998-07-16 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
WO1999014239A1 (en) * 1997-09-12 1999-03-25 Wolf Georg Forssmann Composition for treating diabetes mellitus and obesity
WO1999043705A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
WO2000025806A1 (en) * 1998-11-04 2000-05-11 Aronne Louis J Method for weight control
WO2000066629A1 (en) * 1999-04-30 2000-11-09 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US20010011071A1 (en) * 1996-08-30 2001-08-02 Liselotte Bjerre Knudsen Derivatives of glp-1 analogs
WO2003057235A2 (en) * 2002-01-10 2003-07-17 Imperial College Innovations Ltd Modification of feeding behavior
WO2004009015A2 (en) * 2002-07-18 2004-01-29 Merck & Co., Inc. Combination therapy for the treatment of obesity
US20040116657A1 (en) * 2001-03-01 2004-06-17 Flatt Peter Raymond Modified peptide
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US20040214837A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040214855A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
WO2005049088A2 (en) * 2003-11-17 2005-06-02 Novartis Ag Combination of a dpp iv inhibitor and an antiobesity or appetite regulating agent
US20050171110A1 (en) * 2003-12-19 2005-08-04 Guixue Yu Azabicyclic heterocycles as cannabinoid receptor modulators
WO2005077072A2 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010011071A1 (en) * 1996-08-30 2001-08-02 Liselotte Bjerre Knudsen Derivatives of glp-1 analogs
WO1998030231A1 (en) * 1997-01-07 1998-07-16 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
WO1999014239A1 (en) * 1997-09-12 1999-03-25 Wolf Georg Forssmann Composition for treating diabetes mellitus and obesity
WO1999043705A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
WO2000025806A1 (en) * 1998-11-04 2000-05-11 Aronne Louis J Method for weight control
WO2000066629A1 (en) * 1999-04-30 2000-11-09 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US20040116657A1 (en) * 2001-03-01 2004-06-17 Flatt Peter Raymond Modified peptide
WO2003057235A2 (en) * 2002-01-10 2003-07-17 Imperial College Innovations Ltd Modification of feeding behavior
WO2004009015A2 (en) * 2002-07-18 2004-01-29 Merck & Co., Inc. Combination therapy for the treatment of obesity
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US20040214837A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040214855A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
WO2005049088A2 (en) * 2003-11-17 2005-06-02 Novartis Ag Combination of a dpp iv inhibitor and an antiobesity or appetite regulating agent
US20050171110A1 (en) * 2003-12-19 2005-08-04 Guixue Yu Azabicyclic heterocycles as cannabinoid receptor modulators
WO2005077072A2 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
GUERDJIKOVA ANNA I ET AL: "Response of recurrent binge eating and weight gain to topiramate in patients with binge eating disorder after bariatric surgery.", OBESITY SURGERY : THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY FOR BARIATRIC SURGERY AND OF THE OBESITY SURGERY SOCIETY OF AUSTRALIA AND NEW ZEALAND FEB 2005, vol. 15, no. 2, February 2005 (2005-02-01), pages 273 - 277, XP009081467, ISSN: 0960-8923 *
HANUSCH-ENSERER U ET AL: "News in gut-brain communication: a role of peptide YY (PYY) in human obesity and following bariatric surgery?", EUROPEAN JOURNAL OF CLINICAL INVESTIGATION JUL 2005, vol. 35, no. 7, July 2005 (2005-07-01), pages 425 - 430, XP002427292, ISSN: 0014-2972 *
MATSON C A ET AL: "Cholecystokinin and leptin act synergistically to reduce body weight.", AMERICAN JOURNAL OF PHYSIOLOGY. REGULATORY, INTEGRATIVE AND COMPARATIVE PHYSIOLOGY. APR 2000, vol. 278, no. 4, April 2000 (2000-04-01), pages R882 - R890, XP002393563, ISSN: 0363-6119 *
MATSON CLAIRE A ET AL: "Synergy between leptin and cholecystokinin (CCK) to control daily caloric intake", PEPTIDES (TARRYTOWN), vol. 18, no. 8, 1997, pages 1275 - 1278, XP009070457, ISSN: 0196-9781 *
MURATORI F ET AL: "Efficacy of sibutramine in subjects who regained weight after bariatric surgery", INTERNATIONAL JOURNAL OF OBESITY, vol. 26, no. Supplement 1, August 2002 (2002-08-01), & NINTH INTERNATIONAL CONGRESS ON OBESITY; SAO PAULO, BRAZIL; AUGUST 24-29, 2002, pages S150, XP009081459, ISSN: 0307-0565 *
REPETTO E M ET AL: "Use of sibutramine in superobese patients undergoing to bariatric surgery", INTERNATIONAL JOURNAL OF OBESITY, vol. 25, no. Supplement 2, May 2001 (2001-05-01), & 11TH EUROPEAN CONGRESS ON OBESITY; VIENNA, AUSTRIA; MAY 30-JUNE 02, 2001, pages S114, XP002427291, ISSN: 0307-0565 *
ZILBERSTEIN BRUNO ET AL: "Topiramate after adjustable gastric banding in patients with binge eating and difficulty losing weight.", OBESITY SURGERY : THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY FOR BARIATRIC SURGERY AND OF THE OBESITY SURGERY SOCIETY OF AUSTRALIA AND NEW ZEALAND 2004 JUN-JUL, vol. 14, no. 6, June 2004 (2004-06-01), pages 802 - 805, XP009081468, ISSN: 0960-8923 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12103951B2 (en) 2022-06-14 2024-10-01 Christopher Joseph Soares Use of CGRP receptor antagonists in neuroprotection and neurological disorders

Also Published As

Publication number Publication date
WO2007055743A2 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
WO2006052608A3 (en) Treatment of obesity and related disorders
TN2010000214A1 (en) Methods for treating obesity and obesity related diseases and disorders
WO2007055743A3 (en) Treatment of obesity and related disorders
IL230241A (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders
IL233634A0 (en) Methods, compositions, and kits for the treatment of medical conditions
NO20081842L (en) Methods and compositions for use in the treatment of patients with autoantibody-positive diseases
EP1893216A4 (en) Methods and compositions for the treatment of ocular disorders
IL188204A0 (en) Combination therapy for the treatment of immunoinflammatory disorders
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
WO2006130690A3 (en) Methods and compositions for inducing brown adipogenesis
IL182222A0 (en) Treatment of bipolar disorders and associated symptoms
IL176968A0 (en) Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
WO2010014595A3 (en) Methods and compositions for delivering therapeutic agents in the treatment of b-cell related disorders
IL200570A0 (en) Combination therapy, composition and methods for the treatment of cardiovascular disorders
EP1968645A4 (en) Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses
EP1858557A4 (en) Methods and compositions for modulating body weight and for treating weight disorders and related diseases
WO2007117356A3 (en) Immunoglobulins from vitiligo plasma for melanoma therapy
IL185684A0 (en) Methods and compositions for modulating body weight and for treating weight disorders and related diseases
IL188056A0 (en) Use of allylmercaptocaptopril for treating or preventing obesity and obesity related diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06824762

Country of ref document: EP

Kind code of ref document: A2